Shares of Kadmon Holdings (NYSE: KDMN) popped by 11% today after the biotech reported second-quarter earnings. The company also provided updates on its drug pipeline.
Revenue in the second quarter was $448,000, which resulted in an operating loss of $26.9 million. Net loss was $27.7 million, or $0.17 per share. The developmental biotech company said results from a recent drug trial were encouraging.
Image source: Getty Images.
Source Fool.com